Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies.

Abstract

Remarkable advances in the management of individuals born with cystic fibrosis (CF) would not have been realized without empiric trial and error by CF clinicians with treatments developed and available for other purposes. As the testing and registration of CF-specific treatments have increased, so too have associated health care costs, particularly those of… (More)

Topics

Cite this paper

@article{VanDevanter2016PotentialFT, title={Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies.}, author={Donald R VanDevanter and Sonya L Heltshe and John J Lipuma}, journal={Annals of the American Thoracic Society}, year={2016}, volume={13 11}, pages={1890-1893} }